104 related articles for article (PubMed ID: 8763880)
1. Immunocytochemical labelling of aerobic and hypoxic mammalian cells using a platinated derivative of EF5.
Matthews J; Adomat H; Farrell N; King P; Koch C; Lord E; Palcic B; Poulin N; Sangulin J; Skov K
Br J Cancer Suppl; 1996 Jul; 27():S200-3. PubMed ID: 8763880
[TBL] [Abstract][Full Text] [Related]
2. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors.
Evans SM; Jenkins WT; Joiner B; Lord EM; Koch CJ
Cancer Res; 1996 Jan; 56(2):405-11. PubMed ID: 8542599
[TBL] [Abstract][Full Text] [Related]
3. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts.
Lee J; Siemann DW; Koch CJ; Lord EM
Int J Cancer; 1996 Jul; 67(3):372-8. PubMed ID: 8707411
[TBL] [Abstract][Full Text] [Related]
4. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts.
Lord EM; Harwell L; Koch CJ
Cancer Res; 1993 Dec; 53(23):5721-6. PubMed ID: 8242628
[TBL] [Abstract][Full Text] [Related]
5. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity.
Koch CJ; Evans SM; Lord EM
Br J Cancer; 1995 Oct; 72(4):869-74. PubMed ID: 7547233
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia in human intraperitoneal and extremity sarcomas.
Evans SM; Hahn SM; Magarelli DP; Zhang PJ; Jenkins WT; Fraker DL; Hsi RA; McKenna WG; Koch CJ
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):587-96. PubMed ID: 11173159
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts.
Vukovic V; Haugland HK; Nicklee T; Morrison AJ; Hedley DW
Cancer Res; 2001 Oct; 61(20):7394-8. PubMed ID: 11606368
[TBL] [Abstract][Full Text] [Related]
8. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide].
Evans SM; Joiner B; Jenkins WT; Laughlin KM; Lord EM; Koch CJ
Br J Cancer; 1995 Oct; 72(4):875-82. PubMed ID: 7547234
[TBL] [Abstract][Full Text] [Related]
9. Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole, EF5, and monoclonal antibodies.
Woods ML; Koch CJ; Lord EM
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):93-101. PubMed ID: 12118570
[TBL] [Abstract][Full Text] [Related]
10. Importance of antibody concentration in the assessment of cellular hypoxia by flow cytometry: EF5 and pimonidazole.
Koch CJ
Radiat Res; 2008 Jun; 169(6):677-88. PubMed ID: 18494550
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia in radiation-induced blood-spinal cord barrier breakdown.
Li YQ; Ballinger JR; Nordal RA; Su ZF; Wong CS
Cancer Res; 2001 Apr; 61(8):3348-54. PubMed ID: 11309291
[TBL] [Abstract][Full Text] [Related]
12. EF5 binding and clinical outcome in human soft tissue sarcomas.
Evans SM; Fraker D; Hahn SM; Gleason K; Jenkins WT; Jenkins K; Hwang WT; Zhang P; Mick R; Koch CJ
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):922-7. PubMed ID: 16458778
[TBL] [Abstract][Full Text] [Related]
13. Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia-ischemia.
Bergeron M; Evans SM; Sharp FR; Koch CJ; Lord EM; Ferriero DM
Neuroscience; 1999; 89(4):1357-66. PubMed ID: 10362320
[TBL] [Abstract][Full Text] [Related]
14. In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors.
Mahy P; De Bast M; Gallez B; Gueulette J; Koch CJ; Scalliet P; Grégoire V
Radiother Oncol; 2003 Apr; 67(1):53-61. PubMed ID: 12758240
[TBL] [Abstract][Full Text] [Related]
15. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
Dragowska WH; Warburton C; Yapp DT; Minchinton AI; Hu Y; Waterhouse DN; Gelmon K; Skov K; Woo J; Masin D; Huxham LA; Kyle AH; Bally MB
Mol Cancer Res; 2004 Nov; 2(11):606-19. PubMed ID: 15561777
[TBL] [Abstract][Full Text] [Related]
16. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
Wang J; Foehrenbacher A; Su J; Patel R; Hay MP; Hicks KO; Wilson WR
Clin Cancer Res; 2012 Mar; 18(6):1684-95. PubMed ID: 22167409
[TBL] [Abstract][Full Text] [Related]
17. Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis.
Mahy P; De Bast M; Gillart J; Labar D; Grégoire V
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):553-6. PubMed ID: 16523307
[TBL] [Abstract][Full Text] [Related]
18. Detection of hypoxia in human squamous cell carcinoma by EF5 binding.
Evans SM; Hahn S; Pook DR; Jenkins WT; Chalian AA; Zhang P; Stevens C; Weber R; Weinstein G; Benjamin I; Mirza N; Morgan M; Rubin S; McKenna WG; Lord EM; Koch CJ
Cancer Res; 2000 Apr; 60(7):2018-24. PubMed ID: 10766193
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia and etanidazole alter radiation-induced apoptosis in HL60 cells but not in MOLT-4 cells.
Inanami O; Sugihara K; Okui T; Hayashi M; Tsujitani M; Kuwabara M
Int J Radiat Biol; 2002 Apr; 78(4):267-74. PubMed ID: 12020438
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma.
Koch CJ; Scheuermann JS; Divgi C; Judy KD; Kachur AV; Freifelder R; Reddin JS; Karp J; Stubbs JB; Hahn SM; Driesbaugh J; Smith D; Prendergast S; Evans SM
Eur J Nucl Med Mol Imaging; 2010 Nov; 37(11):2048-59. PubMed ID: 20585774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
